EUVIMEDEUVIMED entdecken
Crossref

Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose

Louise E Bechmann iD, Frida Emanuelsson iD, Børge G Nordestgaard iD, Marianne Benn iD

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvad122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Louise E Bechmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Brain Ischemia, Stroke, Myocardial Infarction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Danish Council for Independent Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Treatment with sodium-glucose co-transporter 2 (SGLT2)-inhibitors reduces the risk of cardiovascular disease and mortality, but the mechanism is unclear. We hypothesized that a functional genetic variant in solute carrier family 5 member 2 (SLC5A2), known to be associated with familial renal glucosuria, would mimic pharmacological SGLT2-inhibition, and thus provide an opportunity to examine potential mediators of the effects on lower risk of cardiovascular disease and mortality. Methods and results We examined 112 712 individuals from the Copenhagen City Heart Study and Copenhagen General Population Study (CCHS + CGPS), 488 687 from the UK Biobank, and 342 499 from FinnGen, genotyped for SLC5A2 rs61742739, c.1961A > G; p.(Asn654Ser). The 2.0% heterozygotes and 0.01% homozygotes were pooled as carriers and compared with the 98% non-carriers. First, we examined the risk of cardiovascular disease and mortality; second, whether carrying the variant was associated with potential mediators of the effect; and third, whether identified potential mediators could explain the observed reduced risk of cardiovascular disease and mortality. In the CCHS + CGPS, carriers vs. non-carries had a 31% lower risk of heart failure, 21% lower risk of myocardial infarction, 16% lower risk of ischaemic heart disease, and 22% lower risk of all-cause mortality. Corresponding values in meta-analyses of the three studies combined were lower risk by 10%, 6%, 6%, and 10%, respectively. The SLC5A2 rs61742739 variant was not associated with a risk of ischaemic stroke or cardiovascular mortality. Of the lower risks observed in CCHS + CGPS, lower plasma glucose mediated 2.0%(P = 0.004) on heart failure, 3.1%(P = 0.09) on myocardial infarction, 4.1%(P = 0.02) on ischaemic heart disease, and 6.0%(P = 0.39) on all-cause mortality; corresponding values in the UK Biobank were 2.9%(P = 0.70), 1.5%(P = 0.77), 4.1%(P = 0.23), and 3.1%(P = 0.21), respectively.

Conclusion

A functional genetic variant in SLC5A2, mimicking SGLT2-inhibition, was associated with a lower risk of heart failure, myocardial infarction, ischaemic heart disease, and all-cause mortality. These effects were at most minimally mediated through lower plasma glucose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesBrain IschemiaStrokeMyocardial InfarctionSodium-Glucose Transporter 2 InhibitorsMyocardial IschemiaHeart FailureDiabetes Mellitus, Type 2HumansBlood GlucoseSodium-Glucose Transporter 2Genetic VariationSodium

Stichwörter der Autor:innen

GlucoseHeart failureIschaemic heart diseaseLipoprotein(a)Myocardial infarctionSodium-glucose co-transporter 2Sodium-glucose co-transporter 2 inhibitors

Substanzen

Blood GlucoseSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSodium

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
  • Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.
  • Department of Clinical Biochemistry, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 1, DK-2730 Herlev, Denmark.
  • The Copenhagen General Population Study, Copenhagen University Hospital-Herlev and Gentofte, Borgmester Ib Juuls Vej 1, DK-2730 Herlev, Denmark.
  • The Copenhagen City Heart Study, Frederiksberg and Bispebjerg Hospital, Copenhagen University Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.

ORCID-Profile: Louise E Bechmann, Frida Emanuelsson, Børge G Nordestgaard, Marianne Benn

Förderung

  • Danish Council for Independent Research

Zitieren

APA

Bechmann, L. E., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2023). Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad122

Vancouver

Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose. Cardiovascular Research. 2023. doi:10.1093/cvr/cvad122

BibTeX
@article{Bechmann2023,
  author = {Bechmann, Louise E and Emanuelsson, Frida and Nordestgaard, Børge G and Benn, Marianne},
  title = {Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvad122}
}
Kostenlos starten →